Laimoud Mohamed, Alanazi Mosleh
Adult Cardiac Surgical Intensive Care Unit (CSICU), King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Critical Care Medicine Department, Cairo University, Cairo, Egypt.
Egypt Heart J. 2020 Oct 27;72(1):74. doi: 10.1186/s43044-020-00108-7.
Veno-arterial ECMO is a life-supporting procedure that can be done to the patients with cardiogenic shock which is associated with hyperlactatemia. The objective of this study was to detect the validity of serial measurements of arterial lactate level in differentiating hospital mortality and neurological outcome after VA-ECMO support for adult patients with cardiogenic shock. All consecutive patients ≥ 18 years admitted with cardiogenic shock and supported with VA-ECMO between 2015 and 2019 in our tertiary care hospital were retrospectively studied.
The study included 106 patients with a mean age of 40.2 ± 14.4 years, a mean BMI of 26.5 ± 7 and mostly males (69.8%). The in-hospital mortality occurred in 56.6% and acute cerebral strokes occurred in 25.5% of the enrolled patients. The non-survivors and the patients with acute cerebral strokes had significantly higher arterial lactate levels at pre-ECMO initiation, post-ECMO peak and after 24 h of ECMO support compared to the survivors and those without strokes, respectively. The peak arterial lactate ≥ 14.65 mmol/L measured after ECMO support had 81.7% sensitivity and 89.1% specificity for predicting hospital mortality [AUROC 0.889, p < 0.001], while the arterial lactate level ≥ 3.25 mmol/L after 24 h of ECMO support had 88.3% sensitivity and 97.8% specificity for predicting hospital mortality [AUROC 0.93, p < 0.001]. The peak lactate ≥ 15.15 mmol/L measured after ECMO support had 70.8% sensitivity and 69% specificity for predicting cerebral strokes [AUROC 0.717, p < 0.001], while the lactate level ≥ 3.25 mmol/L after 24 h of ECMO support had 79.2% sensitivity and 72.4% specificity for predicting cerebral strokes [AUROC 0.779, p < 0.001]. Progressive hyperlactatemia (OR = 1.427, 95% CI 1.048-1.944, p = 0.024) and increasing SOFA score after 48 h (OR = 1.819, 95% CI 1.374-2.409, p < 0.001) were significantly associated with in-hospital mortality after VA-ECMO support. Post hoc analysis detected a significantly high frequency of hypoalbuminemia in the non-survivors and in the patients who developed acute cerebral strokes during VA-ECMO support.
Progressive hyperlactatemia after VA-ECMO initiation for adult patients with cardiogenic shock is a sensitive and specific predictor of hospital mortality and acute cerebrovascular strokes. According to our results, we could recommend early VA-ECMO initiation to achieve adequate circulatory support and better outcome.
静脉-动脉体外膜肺氧合(VA-ECMO)是一种可用于治疗伴有高乳酸血症的心源性休克患者的生命支持治疗手段。本研究的目的是检测连续测量动脉血乳酸水平在预测VA-ECMO支持的成年心源性休克患者院内死亡率及神经功能转归方面的有效性。我们对2015年至2019年期间在我院三级医疗中心接受VA-ECMO支持的所有年龄≥18岁的心源性休克连续入院患者进行了回顾性研究。
本研究纳入106例患者,平均年龄40.2±14.4岁,平均体重指数26.5±7,男性居多(69.8%)。56.6%的患者发生院内死亡,25.5%的患者发生急性脑卒中。与存活患者及无脑卒中患者相比,非存活患者及急性脑卒中患者在ECMO启动前、ECMO支持后乳酸峰值及ECMO支持24小时后的动脉血乳酸水平显著更高。ECMO支持后测得的动脉血乳酸峰值≥14.65 mmol/L预测院内死亡率的敏感度为81.7%,特异度为89.1%[曲线下面积(AUROC)0.889,p<0.001],而ECMO支持24小时后动脉血乳酸水平≥3.25 mmol/L预测院内死亡率的敏感度为88.3%,特异度为97.8%[AUROC 0.93,p<0.001]。ECMO支持后测得的乳酸峰值≥15.15 mmol/L预测脑卒中的敏感度为70.8%,特异度为69%[AUROC 0.717,p<0.001],而ECMO支持24小时后乳酸水平≥3.25 mmol/L预测脑卒中的敏感度为79.2%,特异度为72.4%[AUROC 0.779,p<0.001]。进行性高乳酸血症(比值比[OR]=1.427,95%置信区间[CI] 1.048-1.944,p=0.024)及48小时后序贯器官衰竭评估(SOFA)评分增加(OR=1.819,95%CI 1.374-2.409,p<0.001)与VA-ECMO支持后的院内死亡显著相关。事后分析发现非存活患者及在VA-ECMO支持期间发生急性脑卒中的患者低白蛋白血症发生率显著更高。
成年心源性休克患者启动VA-ECMO后出现的进行性高乳酸血症是院内死亡率及急性脑血管病的敏感且特异的预测指标。根据我们的研究结果,我们建议早期启动VA-ECMO以实现充分的循环支持并改善预后。